Tiffany Pon, PharmD

Professor of Clinical Pharmacy
Department of Clinical Pharmacy
Glocke
[email protected]
Phone: +1 916 734-7726
Fax: +1 916 703-4008
521 Parnassus Avenue, Rm 3rd flr
UCSF Box 0622
San Francisco, CA 94117
United States

Links

UCSF Profiles Experiential Education

Affiliations

Education programs

Regional Program Director, Greater Sacramento Program, PharmD Degree Program

External affiliations

UC Davis Medical Center

What I do

I completed specialty training in cardiology and currently practice inpatient internal medicine. My primary clinical research focus is in anticoagulation. I also have educational research interests in experiential education.

Departmental research area

clinical research
education research

My research expertise

cardiology, internal medicine

Professional background

Degrees

PharmD, Purdue University College of Pharmacy, 2011
BS, Neurobiology, Physiology, and Behavior, University of California, Davis, 2006

Licensure and certifications

Pharmacotherapy Specialist, Board Certified, 2012
Licentiate in Pharmacy, California State Board of Pharmacy, 2011

Biography

Dr. Tiffany Pon is an Associate Professor of Clinical Pharmacy in the Department of Clinical Pharmacy at the University of California, San Francisco. Her clinical practice site is at the University of California, Davis Medical Center (UCDMC) where she provides clinical services in internal medicine. She is also the Program Director for the Greater Sacramento Area Experiential Education site. Research interests primarily involve anticoagulation (dosing and application in special populations) and experiential education. She is also passionate about leadership within the profession and is an active member of the American College of Clinical Pharmacy.

Research keywords

  • antithrombins
  • Cesarean Section
  • Heparin
  • anticoagulants
  • Brain Neoplasms
  • Thrombosis
  • Blood Platelets
  • Renal Dialysis
  • Gastrointestinal Neoplasms
  • Pre-Exposure Prophylaxis
  • Heparin, Low-Molecular-Weight
  • Venous Thromboembolism
  • Thrombocytopenia
  • Kidney Failure, Chronic
  • Enoxaparin
1. Most recent School of Pharmacy primary faculty hires, by department
2. Update from the Dean - Fall 2013
1. Long Award for Excellence in Teaching, University of California, San Francisco, 2017
2. Apples of Preceptor Award, University of California, San Francisco, 2016-2021
3. Long Award for Excellence in Teaching, University of California, San Francisco, 2014
4. Pharmacy Resident of the Year, UC Davis Medical Center, 2012

Publications

Guan T, Laguna A, Soares A, Legasto CS, Block S, Saunders IM, Alvarez K, Pon T, Patel N, Mahajan A, Lee A. Evaluation of direct oral anticoagulants versus low molecular weight heparins for venous thromboembolism treatment in patients with gastrointestinal malignancies. J Thromb Thrombolysis. 2023 Oct; 56(3):439-446.
Knueppel P, Bang SH, Troyer C, Barriga A, Shin J, Cadiz CL, Abdo C, McCart T, Huynh B, Stevens C, Zhou C, Yang NT, Wilson M, Pon T. Evaluation of standard versus reduced dose apixaban for the treatment of venous thromboembolism in patients with severe renal disease (ESRD-VTE). Thromb Res. 2022 12; 220:91-96.
Jefferson Cua, PharmD, BCIDP; Kei Takamura, PharmD, BCPS, BCPP; Kathie H. Le, Pharm.D, BCPS; Matthew Serna, PharmD, BCPS; Denise Roach, PharmD, BCGP; Elle Zhu, PharmD; Tiffany Pon, PharmD, BCPS. Cost Comparison of Oral Linezolid and Intravenous Vancomycin for Empiric Treatment of Suspected MRSA Pneumonia. Journal of Contemporary Pharmacy Practice. 2022; 70(2):14-20.
Dang NV, Pon TK, Hellier YM. Pharmacy Resident Perspectives on the Layered Learning Practice Model. Hosp Pharm. 2022 Aug; 57(4):425-434.
Tsao M, Laikijrung C, Tran A, Pon T, Roach D, Liu B, Le K. Optimizing quality of care in patients admitted with chronic obstructive pulmonary disease exacerbation. Chron Respir Dis. 2022 Jan-Dec; 19:14799731211073348.
Lee A, Oley F, Lo M, Fong R, McGann M, Saunders I, Block S, Mahajan A, Pon TK. Direct oral anticoagulants or low-molecular-weight heparins for venous thromboembolism in patients with brain tumors. Thromb Res. 2021 Dec; 208:148-155.
Pon TK, Wessel N, Cagonot V, Delmonte R, Roach D, Finta L. Utilization of venous thromboembolism prophylaxis in American hospitalized pregnant women undergoing cesarean section. Int J Clin Pharm. 2019 Feb; 41(1):264-271.
Pon TK, Mahajan A, Rosenberg A, Amin A, Shah D, Jenkins I, Gupta V, Hofmann H, Bejjani A, White R. Platelet response to direct thrombin inhibitor or fondaparinux treatment in patients with suspected heparin-induced thrombocytopenia. J Thromb Thrombolysis. 2018 May; 45(4):536-542.
Phillips HJ, Dangler A, Klem PM, Chu F, Pon T, Liewer S, Thompson Bastin ML, Halfpap JJ, Fish J, Stun L, Varughese CA. Preceptor development: Responses to frequently asked questions from preceptors in academic hospitals. Am J Health Syst Pharm. 2016 May 01; 73(9):e261-6.
Dager WE, Tsu LV, Pon TK. Considerations for Systemic Anticoagulation in ESRD. Semin Dial. 2015 Jul-Aug; 28(4):354-62.
Cutler TW, Chuang A, Huynh TD, Witt RG, Branch J, Pon T, White R. A retrospective descriptive analysis of patient adherence to dabigatran at a large academic medical center. J Manag Care Spec Pharm. 2014 Oct; 20(10):1028-34.
Pon TK, Dager WE, Roberts AJ, White RH. Subcutaneous enoxaparin for therapeutic anticoagulation in hemodialysis patients. Thromb Res. 2014 Jun; 133(6):1023-8.